The prophylactic HIV drugs industry size is projected to be worth US$32,516.1 million in 2023 and US$31,278.5 million in 2022. Growth in the market is primarily due to increased R&D investment in HIV clinical trials by pharmaceutical and biotechnology companies, increased HIV drug approvals, and an increase in the prevalence of HIV in the population. …